Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Acro Biomedical (ACBM) Cost of Revenue (2017 - 2022)

Acro Biomedical (ACBM) has 6 years of Cost of Revenue data on record, last reported at $296000.0 in Q4 2022.

  • For Q4 2022, Cost of Revenue fell 33.93% year-over-year to $296000.0; the TTM value through Sep 2023 reached $296000.0, down 55.82%, while the annual FY2022 figure was $518000.0, 44.78% down from the prior year.
  • Cost of Revenue reached $296000.0 in Q4 2022 per ACBM's latest filing, up from $222000.0 in the prior quarter.
  • Across five years, Cost of Revenue topped out at $2.2 million in Q3 2018 and bottomed at -$1.0 million in Q4 2019.
  • Average Cost of Revenue over 5 years is $731509.1, with a median of $448000.0 recorded in 2021.
  • Peak YoY movement for Cost of Revenue: tumbled 185.11% in 2019, then soared 217.14% in 2022.
  • A 5-year view of Cost of Revenue shows it stood at $1.2 million in 2018, then tumbled by 185.11% to -$1.0 million in 2019, then surged by 150.96% to $528560.0 in 2020, then decreased by 15.24% to $448000.0 in 2021, then crashed by 33.93% to $296000.0 in 2022.
  • Per Business Quant database, its latest 3 readings for Cost of Revenue were $296000.0 in Q4 2022, $222000.0 in Q1 2022, and $448000.0 in Q4 2021.